News|Articles|November 16, 2026

FDA Issues CRL to Ivonescimab Plus Chemo for Locally Advanced or Metastatic NSCLC

Author(s)OncLive Staff
Fact checked by: Ashling Wahner
Listen
0:00 / 0:00

Key Takeaways

  • FDA concluded substantial evidence of effectiveness was lacking because OS was not statistically improved, and PFS benefit alone did not support a favorable benefit–risk profile in this post–EGFR TKI setting.
  • HARMONi randomized 438 patients to ivonescimab 20 mg/kg Q3W or placebo with carboplatin (AUC5) plus pemetrexed; dual primary end points were OS and IRRC-assessed PFS per RECIST 1.1.
SHOW MORE

The FDA cited the lack of a significant OS benefit in HARMONi for ivonescimab plus chemotherapy after EGFR TKI therapy in NSCLC.

The FDA has issued a complete response letter to the biologics license application seeking the approval of ivonescimab (SMT112; AK112), a PD-1/VEGF bispecific antibody, in combination with platinum-containing chemotherapy for the treatment of patients with locally advanced or metastatic non–small cell lung cancer whose disease had been previously treated with an EGFR TKI.¹

The FDA determined that the biologics license application (BLA) cannot be approved as submitted because substantial evidence of effectiveness was not shown due to the absence of a statistically significant overall survival improvement with ivonescimab plus chemotherapy vs placebo plus chemotherapy, and that a progression-free survival benefit without a significant overall survival (OS) benefit does not support a favorable benefit-risk profile.

The BLA submission was supported by data from the global, randomized, double-blind phase 3 HARMONi trial (NCT06396065) that were presented at the 2025 IASLC World Conference on Lung Cancer.2,3 The trial met 1 of its 2 primary end points. The median progression-free survival (PFS) by independent radiology review committee was 6.8 months with ivonescimab plus chemotherapy (n = 172) vs 4.4 months with placebo plus chemotherapy (n = 173; HR, 0.52; 95% CI, 0.41-0.66; P < .0001) at a median follow-up of 22.3 months. The respective median OS values were 16.8 months (n = 219) vs 14.0 months (n = 219; HR, 0.79; 95% CI, 0.62-1.01; P = .0570), a difference that did not reach statistical significance.

“We are disappointed for patients and their families awaiting additional treatment options in this setting,” Robert W. Duggan, chairman and co-chief executive officer of Summit Therapeutics, stated in a news release. ““With 5 positive phase III studies between Summit and Akeso, nothing changes with respect to our ever-growing belief in the opportunity for ivonescimab and our determination to advance ivonescimab’s development. Our mission remains to improve outcomes for patients facing significant unmet needs, which is work worth doing, and we will continue through our expansive clinical development program.”

How was the HARMONi trial designed?

Eligible adult patients needed to have locally advanced or metastatic nonsquamous non–small cell lung cancer (NSCLC) with a sensitizing EGFR mutation, disease progression on a third-generation EGFR TKI, an ECOG performance status of 0 or 1, and any PD-L1 expression level.1,3 Patients (N = 438) were randomly assigned 1:1 to receive ivonescimab at 20 mg/kg or placebo every 3 weeks, each in combination with carboplatin dosed at an area under the curve of 5 every 3 weeks for 4 cycles and pemetrexed at 500 mg/m² every 3 weeks. OS and independent radiology review committee (IRRC)–assessed PFS per RECIST 1.1 criteria served as the dual primary end points, and secondary end points included objective response rate by IRRC, duration of response, and safety.

What additional efficacy data from HARMONi supported the ivonescimab BLA submission?

The 6-month PFS rate was 54.0% with ivonescimab vs 34.7% with placebo, and the 12-month rates were 25.4% vs 8.3%, respectively.3 By IRRC, the respective objective response rates were 45% vs 34%, the disease control rates were 84% vs 73%, and the median durations of response were 7.6 months (95% CI, 5.5-10.6) vs 4.2 months (95% CI, 2.9-4.7).

With longer follow-up in Western patients (data cutoffs of September 2025 for North America and Europe and April 2025 for Asia), the median OS remained 16.8 months in the ivonescimab arm vs 14.0 months in the placebo arm (HR, 0.78; 95% CI, 0.62-0.98; nominal P = .0332). The median follow-up in North America and Europe was 9.2 months at the primary OS analysis and 13.7 months at the longer follow-up, when the median OS values in those respective analyses from that region were 17.0 months vs 14.0 months (HR, 0.84; 95% CI, 0.53-1.32).

What is the safety profile of ivonescimab?

Among treated patients (n = 218 per arm), treatment-related adverse effects of any grade occurred in 95.0% of those treated with ivonescimab plus chemotherapy vs 93.1% of those treated with placebo plus chemotherapy. Among patients in these respective arms, grade 3 or higher treatment-related adverse effects (TRAEs) occurred in 50.0% vs 42.2%, serious TRAEs occurred in 28.0% vs 15.1%, TRAEs led to discontinuation in 7.3% vs 5.0%, and TRAEs led to death in 1.8% vs 2.3%.

Grade 3 or higher immune-related adverse effects occurred in 9.6% vs 6.0%, and grade 3 or higher VEGF-related TRAEs occurred in 7.3% vs 3.2%. The most common grade 3 or higher TRAEs were decreased neutrophil count (ivonescimab arm, 19.3%; placebo arm, 16.5%), decreased white blood cell count (12.8%; 11.0%), and decreased platelet count (12.4%; 6.4%). Pneumonitis or interstitial lung disease occurred in 2.8% vs 1.8% of patients, respectively, with grade 3 or higher events reported in 1.4% of patients in each arm, and grade 3 or higher bleeding occurred in less than 1% of patients.

References

  1. Summit Therapeutics provides update regarding ivonescimab biologics license application. News release. Summit Therapeutics Inc. November 15, 2026. Accessed November 16, 2026. https://smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Provides-Update-Regarding-Ivonescimab-Biologics-License-Application/
  2. Summit Therapeutics announces US FDA acceptance of biologics license application (BLA) seeking approval for ivonescimab in combination with chemotherapy in treatment of patients with EGFRm NSCLC post-TKI therapy. News release. Summit Therapeutics Inc. January 29, 2026. Accessed November 16, 2026. https://www.smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Announces-U-S--FDA-Acceptance-of-Biologics-License-Application-BLA-Seeking-Approval-for-Ivonescimab-in-Combination-with-Chemotherapy-in-Treatment-of-Patients-with-EGFRm-NSCLC-Post-TKI-Therapy/default.aspx
  3. Goldman JW, Passaro A, Laskin J, et al. Ivonescimab vs placebo plus chemo, phase 3 in patients with EGFR+ NSCLC progressed with 3rd gen EGFR-TKI treatment: HARMONi. Presented at: 2025 IASLC World Conference on Lung Cancer; September 6-9, 2025; Barcelona, Spain. Abstract 4808.

Related to this article